Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT01659008 Recruiting - Clinical trials for Menstrual Cycle and Uterine Bleeding Disorders

Estradiol vs Lysteda in Treatment of Heavy Menstrual Bleeding

Start date: June 2012
Phase: N/A
Study type: Interventional

Treatment with Estradiol is non-inferior to treatment with Tranexamic acid in reducing the amount and duration of menstrual blood loss in women with cyclic heavy menstrual bleeding

NCT ID: NCT01634828 Recruiting - Clinical trials for Improved Intraoperative Blood Loss Estimates

Method for Improved Intraoperative Blood Loss Estimates

EBL
Start date: July 2012
Phase: N/A
Study type: Observational

The purpose of this study is to develop a mathematical algorithm which the investigators plan to use to more accurately estimate intraoperative blood loss.

NCT ID: NCT01618890 Recruiting - Liver Cirrhosis Clinical Trials

Hepatic Venous Pressure Gradient-guided Versus Standard Beta-blocker Therapy in Primary Prevention of Variceal Bleeding

Porthos
Start date: September 2012
Phase: Phase 3
Study type: Interventional

Study hypothesis: Hepatic venous pressure gradient (HVPG)-directed primary prophylaxis with nonselective beta-blocker therapy (NSBB) leads to a reduction in first variceal bleeding episodes and is cost-effective in the long term. Study design: A multi-center randomized controlled study comparing nonselective beta-blocker therapy guided by the hemodynamic response as determined by the difference in HVPG before and after starting oral NSBB therapy, to standard heart rate-guided NSBB therapy in patients with esophageal varices due to liver cirrhosis without a history of esophageal variceal hemorrhage. Primary study parameters/outcome of the study: First variceal bleeding episodes occurring within the first two years. Secondary study parameters/outcome of the study: - Mortality - Occurrence of other cirrhosis-related complications - Occurrence of hepatocellular carcinoma - Costs of treatments - Adverse effects

NCT ID: NCT01600612 Recruiting - Clinical trials for Postpartum Hemorrhage

Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial

Start date: September 2012
Phase: N/A
Study type: Interventional

Postpartum hemorrhage (PPH) is the leading cause of maternal death worldwide, with an estimated mortality of 140 000 per year. Uterine atony is one of the most important causes of PPH. The traditional treatment of which is the use of uterotonic agents. Oxytocin is the most conventional drug which was proved effective. However, it has the shortcomings of short half life and the necessity of intravenous administration. Misopristol, and more recently Carbetocin were introduced for treatment of atonic PPP not responding to Oxytocin. Aim of the study is to evaluate the effectiveness of Carbetocin, Misopristol, and Oxytocin for treatment of atonic PPH.

NCT ID: NCT01579201 Recruiting - Clinical trials for Postpartum Hemorrhage

ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery

Start date: March 2012
Phase: Phase 4
Study type: Interventional

The purpose of this trial is to determine the effective dose of carbetocin which would prevent the occurrence of postpartum uterine atony in 90% of women undergoing an elective cesarean delivery.

NCT ID: NCT01537263 Recruiting - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Ultrasound Perfusion Imaging After Aneurysmal Subarachnoid Hemorrhage

PSAB
Start date: January 2012
Phase: N/A
Study type: Observational

The purpose of this study is to examine wether delayed cerebral ischemia can be predicted by ultrasound brain perfusion imaging in patients with aneurysmal subarachnoid hemorrhage (SAH).

NCT ID: NCT01465256 Recruiting - Clinical trials for Bleeding Complication During Colon Polypectomy

Postpolypectomy Bleeding in Patients With Antiplatelet Therapy

Start date: April 2012
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the use of aspirin prior to colonoscopy increases the risk of post polypectomy bleeding. The primary end point is comparison of bleeding rates after polypectomy of a continuous aspirin group and temporally aspirin-quit group. The secondary end point is analysis of risk factors which affect early or delayed post polypectomy bleeding.

NCT ID: NCT01451658 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol (S-HCC)

Start date: December 2009
Phase: Phase 4
Study type: Interventional

Patients with hepatocellular carcinoma and esophageal varices bleeding were randomized to undergo endoscopic ligation alone (group A) and additive propranolol treatment (group B) after stabilization of their first acute bleeding.

NCT ID: NCT01400360 Recruiting - Clinical trials for Cerebral Vasospasm After Subarachnoid Hemorrhage

Invasive Diagnostic and Therapeutic Management of Cerebral Vasospasm After Aneurysmatic Subarachnoid Hemorrhage

IMCVS
Start date: August 2009
Phase: N/A
Study type: Interventional

Cerebral vasospasm(CVS) after subarachnoid hemorrhage (SAH) results in a considerable amount of transient or even permanent neurological deficits and poor outcome of the patients. Transluminal Balloon angioplasty (TBA) or intraarterial application of vasodilators represents a rescue therapy for severe CVS. Indication, duration and efficacy of this treatment, however, is still under debate. Aim of the study is to investigate if such a rescue treatment can significantly reduce new delayed ischemic cerebral deficits after SAH. Hypothesis is that the occurance of delayed infarcts can be reduced by repetetive intraarterial therapy to more than 50 %.

NCT ID: NCT01391052 Recruiting - Menorrhagia Clinical Trials

Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding

Mirena IUD
Start date: January 2011
Phase: Phase 4
Study type: Interventional

Problematic uterine bleeding after the insertion of the LNG IUS is a well documented side effect. The levonorgestrel intrauterine system (LNG IUS) was approved for treatment of heavy menstrual bleeding (HMB) by the FDA in October 2009. To reduce the incidence and severity of post-insertional uterine bleeding, pretreatment with norethindrone acetate may effectively slough the endometrium prior to insertion of the LNG IUS.